Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Lapham

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 14, 2024
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'-<i>O</i>-Glucuronide Formation as a Selective UGT2B4 Probe ReactionKimberly Lapham, Nicholas Ferguson, Mark Niosi, et al.
The AAPS Journal|September 25, 2024
UGT2B10 is the Major UDP-Glucuronosyltransferase 2B Isoform Involved in the Metabolism of Lamotrigine and is Implicated in the Drug-Drug Interaction with Valproic AcidLloyd Wei Tat Tang, Kimberly Lapham, Theunis C Goosen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 2, 2024
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human HepatocytesLloyd Wei Tat Tang, Ethan DaSilva, Kimberly Lapham, et al.
Journal of Medicinal Chemistry|January 6, 2025
Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug DesignThomas Schroeter, Kimberly Lapham, Manthena V S Varma, et al.
Pharmacology & Therapeutics|September 27, 2020
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotypingJohn O Miners, Andrew Rowland, Jonathan J Novak, et al.
The AAPS Journal|February 4, 2025
Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and PregnancyIain Gardner, Aki T Heikkinen, Lloyd Wei Tat Tang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 6, 2020
In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 EnzymesKimberly Lapham, Ernesto Callegari, Julie Cianfrogna, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 24, 2013
Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptorAmit S Kalgutkar, Tim F Ryder, Gregory S Walker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.
ACS Chemical Biology|February 1, 2019
Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474Zhen Huang, Daisuke Ogasawara, Uthpala I Seneviratne, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 14, 2024
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'-<i>O</i>-Glucuronide Formation as a Selective UGT2B4 Probe ReactionKimberly Lapham, Nicholas Ferguson, Mark Niosi, et al.
The AAPS Journal|September 25, 2024
UGT2B10 is the Major UDP-Glucuronosyltransferase 2B Isoform Involved in the Metabolism of Lamotrigine and is Implicated in the Drug-Drug Interaction with Valproic AcidLloyd Wei Tat Tang, Kimberly Lapham, Theunis C Goosen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 2, 2024
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human HepatocytesLloyd Wei Tat Tang, Ethan DaSilva, Kimberly Lapham, et al.
Journal of Medicinal Chemistry|January 6, 2025
Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug DesignThomas Schroeter, Kimberly Lapham, Manthena V S Varma, et al.
Pharmacology & Therapeutics|September 27, 2020
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotypingJohn O Miners, Andrew Rowland, Jonathan J Novak, et al.
The AAPS Journal|February 4, 2025
Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and PregnancyIain Gardner, Aki T Heikkinen, Lloyd Wei Tat Tang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 6, 2020
In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 EnzymesKimberly Lapham, Ernesto Callegari, Julie Cianfrogna, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 24, 2013
Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptorAmit S Kalgutkar, Tim F Ryder, Gregory S Walker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.
ACS Chemical Biology|February 1, 2019
Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474Zhen Huang, Daisuke Ogasawara, Uthpala I Seneviratne, et al.
Pageof 3